Christine Culy

Summary

Affiliation: Prous Science
Country: Spain

Publications

  1. ncbi Omalizumab: an effective anti-IgE treatment for allergic asthma and rhinitis
    Thomas B Casale
    Medical Information Department, Prous Science, Provença 388, 08025 Barcelona, Spain
    Drugs Today (Barc) 40:367-76. 2004
  2. ncbi Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes
    Sandra L Cox
    Medical Information Department, Prous Science, 08025 Barcelona, Spain
    Drugs Today (Barc) 40:633-43. 2004
  3. ncbi Bevacizumab: antiangiogenic cancer therapy
    Christine Culy
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 41:23-36. 2005

Collaborators

  • Thomas B Casale
  • Sandra L Cox

Detail Information

Publications3

  1. ncbi Omalizumab: an effective anti-IgE treatment for allergic asthma and rhinitis
    Thomas B Casale
    Medical Information Department, Prous Science, Provença 388, 08025 Barcelona, Spain
    Drugs Today (Barc) 40:367-76. 2004
    ..Omalizumab has a good safety profile, with only mild to intermediate drug-related adverse events...
  2. ncbi Rosiglitazone maleate/metformin hydrochloride: a new formulation therapy for type 2 diabetes
    Sandra L Cox
    Medical Information Department, Prous Science, 08025 Barcelona, Spain
    Drugs Today (Barc) 40:633-43. 2004
    ..This review summarizes the available evidence on the clinical efficacy and safety of rosiglitazone maleate and metformin hydrochloride combination therapy in patients with type 2 diabetes...
  3. ncbi Bevacizumab: antiangiogenic cancer therapy
    Christine Culy
    Medical Information Department, Prous Science, Barcelona, Spain
    Drugs Today (Barc) 41:23-36. 2005
    ....